Historically, the median overall survival of metastatic melanoma patients was less than 1 year and long-term survivors were rare. Recent advances in therapies have dramatically shifted this landscape...
Areas covered: This is a comprehensive review of the literature on the role of pembrolizumab in melanoma.
The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free...
Bristol Myers Squibb announced the Phase III CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy met its primary endpoint of improved overall survival (OS) compared to investigator’s choice of sorafenib or lenvatinib at a pre-specified interim analysis.
UK's NICE has recommended that the combination of Opdivo + Yervoy (nivolumab + ipilimumab), from BMS, for the treatment of...
BMS announced that the FDA has accepted for filing and review a supplemental Biologics License Application (sBLA) for the combination...
Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK inhibitor combinations.
Study 004, a dose-ranging Phase 1 trial (n=86) evaluating the safety and anti-tumor activity of investigational PD-1 receptor blocker, nivolumab,...
Bristol-Myers Squibb Company announced follow up results from Study -004, a multi-arm Phase 1b dose-ranging trial evaluating the safety and...
The EMA has validated the application from BMS for Opdivo (nivolumab) + Yervoy (ipilimumab) to treat melanoma, the proposed new...